These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 19455605)
21. Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Chen YC; Giovannucci E; Kraft P; Lazarus R; Hunter DJ Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1982-9. PubMed ID: 17932345 [TBL] [Abstract][Full Text] [Related]
22. The role of IGFBP3 functional polymorphisms in the risk of gastric cancer in a high-risk Chinese population. Chen W; Wang L; Ke Q; Jin G; Tan Y; Zhou Y; Hu Z; Ma H; Wang J; Hua Z; Ding W; Shen J; Xu Y; Shen H Eur J Cancer Prev; 2008 Apr; 17(2):82-7. PubMed ID: 18287864 [TBL] [Abstract][Full Text] [Related]
23. Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. Johansson M; McKay JD; Wiklund F; Rinaldi S; Verheus M; van Gils CH; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R J Clin Endocrinol Metab; 2007 Dec; 92(12):4820-6. PubMed ID: 17911177 [TBL] [Abstract][Full Text] [Related]
24. Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study. Kjellman A; Akre O; Norming U; Törnblom M; Gustafsson O Eur Urol; 2008 Jan; 53(1):106-11. PubMed ID: 17482753 [TBL] [Abstract][Full Text] [Related]
25. The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Langsenlehner T; Langsenlehner U; Renner W; Kapp KS; Krippl P; Hofmann G; Clar H; Pummer K; Mayer R Prostate; 2008 Feb; 68(3):264-8. PubMed ID: 18163425 [TBL] [Abstract][Full Text] [Related]
26. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia]. Povelitsa EA; Nabyrov EA Vopr Onkol; 2008; 54(5):596-601. PubMed ID: 19069473 [TBL] [Abstract][Full Text] [Related]
27. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Xu J; Lowey J; Wiklund F; Sun J; Lindmark F; Hsu FC; Dimitrov L; Chang B; Turner AR; Liu W; Adami HO; Suh E; Moore JH; Zheng SL; Isaacs WB; Trent JM; Grönberg H Cancer Epidemiol Biomarkers Prev; 2005 Nov; 14(11 Pt 1):2563-8. PubMed ID: 16284379 [TBL] [Abstract][Full Text] [Related]
28. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. Tsuchiya N; Wang L; Suzuki H; Segawa T; Fukuda H; Narita S; Shimbo M; Kamoto T; Mitsumori K; Ichikawa T; Ogawa O; Nakamura A; Habuchi T J Clin Oncol; 2006 May; 24(13):1982-9. PubMed ID: 16648498 [TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? Meinbach DS; Lokeshwar BL Urol Oncol; 2006; 24(4):294-306. PubMed ID: 16818181 [TBL] [Abstract][Full Text] [Related]
30. Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Meyer A; Schürmann P; Ghahremani M; Kocak E; Brinkhaus MJ; Bremer M; Karstens JH; Hagemann J; Machtens S; Dörk T Urol Oncol; 2009; 27(4):373-6. PubMed ID: 18625567 [TBL] [Abstract][Full Text] [Related]
31. Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene. Selinski S; Lehmann ML; Blaszkewicz M; Ovsiannikov D; Moormann O; Guballa C; Kress A; Truss MC; Gerullis H; Otto T; Barski D; Niegisch G; Albers P; Frees S; Brenner W; Thüroff JW; Angeli-Greaves M; Seidel T; Roth G; Volkert F; Ebbinghaus R; Prager HM; Lukas C; Bolt HM; Falkenstein M; Zimmermann A; Klein T; Reckwitz T; Roemer HC; Hartel M; Weistenhöfer W; Schöps W; Rizvi SA; Aslam M; Bánfi G; Romics I; Ickstadt K; Hengstler JG; Golka K Arch Toxicol; 2012 Feb; 86(2):195-203. PubMed ID: 21892705 [TBL] [Abstract][Full Text] [Related]
32. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Gu F; Schumacher FR; Canzian F; Allen NE; Albanes D; Berg CD; Berndt SI; Boeing H; Bueno-de-Mesquita HB; Buring JE; Chabbert-Buffet N; Chanock SJ; Clavel-Chapelon F; Dumeaux V; Gaziano JM; Giovannucci EL; Haiman CA; Hankinson SE; Hayes RB; Henderson BE; Hunter DJ; Hoover RN; Johansson M; Key TJ; Khaw KT; Kolonel LN; Lagiou P; Lee IM; LeMarchand L; Lund E; Ma J; Onland-Moret NC; Overvad K; Rodriguez L; Sacerdote C; Sánchez MJ; Stampfer MJ; Stattin P; Stram DO; Thomas G; Thun MJ; Tjønneland A; Trichopoulos D; Tumino R; Virtamo J; Weinstein SJ; Willett WC; Yeager M; Zhang SM; Kaaks R; Riboli E; Ziegler RG; Kraft P Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2877-87. PubMed ID: 20810604 [TBL] [Abstract][Full Text] [Related]
33. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Zheng SL; Liu W; Wiklund F; Dimitrov L; Bälter K; Sun J; Adami HO; Johansson JE; Sun J; Chang B; Loza M; Turner AR; Bleecker ER; Meyers DA; Carpten JD; Duggan D; Isaacs WB; Xu J; Grönberg H Prostate; 2006 Oct; 66(14):1556-64. PubMed ID: 16921508 [TBL] [Abstract][Full Text] [Related]
34. Interrelationships between dietary restriction, the IGF-I axis, and expression of vascular endothelial growth factor by prostate adenocarcinoma in rats. Powolny AA; Wang S; Carlton PS; Hoot DR; Clinton SK Mol Carcinog; 2008 Jun; 47(6):458-65. PubMed ID: 18058807 [TBL] [Abstract][Full Text] [Related]
35. Common genetic variation of insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, and acid labile subunit in relation to serum IGF-I levels and mammographic density. Taverne CW; Verheus M; McKay JD; Kaaks R; Canzian F; Grobbee DE; Peeters PH; van Gils CH Breast Cancer Res Treat; 2010 Oct; 123(3):843-55. PubMed ID: 20155489 [TBL] [Abstract][Full Text] [Related]
36. Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer. Levin AM; Zuhlke KA; Ray AM; Cooney KA; Douglas JA Prostate; 2007 Oct; 67(14):1507-13. PubMed ID: 17683075 [TBL] [Abstract][Full Text] [Related]
37. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cheng I; Penney KL; Stram DO; Le Marchand L; Giorgi E; Haiman CA; Kolonel LN; Pike M; Hirschhorn J; Henderson BE; Freedman ML Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1993-7. PubMed ID: 17035411 [TBL] [Abstract][Full Text] [Related]
38. Hereditary prostate cancer: clinical characteristics and survival. Bratt O; Damber JE; Emanuelsson M; Grönberg H J Urol; 2002 Jun; 167(6):2423-6. PubMed ID: 11992050 [TBL] [Abstract][Full Text] [Related]
39. Y chromosome haplotypes and prostate cancer in Sweden. Lindström S; Adami HO; Adolfsson J; Wiklund F Clin Cancer Res; 2008 Oct; 14(20):6712-6. PubMed ID: 18927315 [TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort. Kesarwani P; Mandhani A; Mittal RD J Urol; 2009 Dec; 182(6):2938-43. PubMed ID: 19846139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]